查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806127

全球幹細胞市場（按細胞類型、細胞來源、技術、應用和最終用戶分類）預測 2025-2030

Stem Cells Market by Cell Type, Cell Source, Technology, Cell Source, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年幹細胞市場規模將達到142.2億美元，2025年將達到157.2億美元，複合年成長率為10.89%，到2030年將達到264.5億美元。

主要市場統計數據
基準年2024年 142.2億美元
預計2025年 157.2億美元
預測年份 2030 264.5億美元
複合年成長率（%） 10.89%

揭示幹細胞創新在治療研究和臨床應用的變革力量和新可能性

幹細胞技術已迅速從學術好奇心發展成為治療創新的前沿，推動了再生醫學、藥物研發和基礎生物學等領域的突破性進展。從人類胚胎幹細胞的開創性分離到誘導性多功能幹細胞的現代掌握，該領域如今已支持各種臨床試驗和商業計畫。對細胞分化、微環境工程和免疫調節的深入研究展現了這些活體療法的多方面潛力，為心血管疾病、神經退化性疾病和組織損傷提供了潛在的治療方法。

監管進步、技術創新和策略合作正在引領模式轉移並重塑幹細胞領域

在監管發展、技術突破和策略合作的推動下，幹細胞生態系統正在經歷模式轉移。全球衛生部門的新指南在病人安全與再生療法快速通道之間取得平衡，從而加速核准並實施同情用藥計畫。同時，CRISPR 平台和整合定序等基因組工程的突破，正在實現對細胞身份和功能的前所未有的控制。

分析2025年美國關稅對幹細胞供應鏈和研究趨勢的廣泛累積影響

美國將於2025年加徵關稅，這為全球幹細胞供應鏈和研究活動帶來了巨大的複雜性。雖然這些措施旨在保護國內製造業，但也影響了細胞培養、基因編輯和生物列印過程中所需的試劑、專用設備和原料的採購。因此，實驗室和生產設施面臨進口成本上升的問題，迫使採購團隊尋找替代供應商和本地生產合作夥伴，以緩解預算壓力。

釋放細胞類型、來源、技術、應用和最終用戶的關鍵細分洞察，以揭示市場機會

深入研究細分洞察，揭示出由多種細胞類型分類、來源、技術平台、組織輸入、應用和最終用戶類別所塑造的微妙模式。研究細胞類型後發現，成體幹細胞、誘導性多功能幹細胞的發展軌跡截然不同。進一步按細胞來源細分，對比了同種異體療法和自體療法，突顯了現成可用性與個人化適用性之間的權衡。

檢驗區域動態，重點關注美洲、歐洲、中東和非洲以及亞太地區的新興驅動力和挑戰

幹細胞領域的區域動態揭示了正在塑造全球應用模式的成長軌跡、創新叢集和法律規範。美洲成熟市場擁有強大的臨床試驗和生產基礎設施，這得益於資金雄厚的研究機構和成熟的生物製藥公司。該地區的監管機構持續完善快速通道，在病患安全與快速取得先進治療方法之間取得平衡。跨境合作和共用創新中心進一步連結了生態系統。

分析影響全球幹細胞研究市場競爭動態的主要企業的策略創新和聯盟

領先的幹細胞公司正在部署差異化策略，透過將深厚的科學研究專長與強大的夥伴關係網路和敏捷的經營模式相結合，獲得競爭優勢。一些大型生物製藥公司已經整合了端到端平台，連接上游細胞採購、基因編輯能力和下游製造，確保整個價值鏈的一致性和可追溯性。這些整合型公司通常會與專業技術公司達成許可和共同開發契約，以加速產品線多元化並縮短臨床開發時間。

為行業領導者制定可行的建議，以促進永續成長、推動創新並應對不斷變化的監管和市場趨勢。

為了在不斷發展的幹細胞生態系統中保持發展勢頭，行業領導者應採取積極主動的多學科方法，將科學創新與卓越營運和監管敏銳性相協調。首先，他們必須投資一個整合的數位框架，該框架將來自研發、製造和臨床營運的資料集中起來，實現即時決策和預測分析，並簡化工作流程。同時，他們必須建立跨職能的管治團隊，以確保從計劃啟動到商業化的整個過程中，監管要求、品質標準和倫理考量都得以執行。

了解我們全面的調查方法，該方法整合了資料來源、相關人員的參與和分析框架，從而提供可靠的幹細胞市場情報

本報告的調查方法融合了定性和定量分析，以捕捉幹細胞領域的多面性。初步的二次研究包括深入查閱同行評審期刊、監管格局、專利格局、會議論文集和技術白皮書，以繪製科學進步和政策發展圖景。這些見解與專有資料庫和行業出版物相結合，以檢驗新興趨勢並識別主要企業。

主要發現摘要：對幹細胞生態系統和轉化研究相關人員的策略意義和未來前景

本執行摘要總結了關於幹細胞研究這一蓬勃發展領域及其在醫療創新中日益擴大的作用的關鍵見解。它探討了新的監管措施、技術進步和策略合作如何重塑這一格局，以及新徵收的關稅如何影響供應鏈和研究的連續性。詳細的細分分析檢驗了不同細胞類型、來源、技術、組織投入、應用和最終用戶的市場規模差異，為相關人員提供了有針對性的切入點和閒置頻段機會。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 誘導多功能細胞在個人化疾病建模和高通量藥物篩檢的進展
  • 使用無支架幹細胞球體生物列印功能組織用於複雜器官再生
  • 針對發炎性腸道疾病症狀的同種異體間質幹細胞療法的快速發展
  • CRISPR編輯造血幹細胞療法的出現，用於治療鐮狀細胞疾病併發症
  • 同種異體神經幹細胞移植在脊髓損傷修復通訊協定中首次獲得監管部門核准
  • 基於幹細胞分泌組衍生的細胞外囊泡的診斷技術商業化用於早期疾病檢測
  • 生技創新者與製藥公司建立策略聯盟，加速以幹細胞為基礎的心臟衰竭治療
  • 自動化幹細胞製造平台的投資趨勢，旨在擴大生產規模並降低治療成本
  • 整合人工智慧驅動的預測分化模型，用於幹細胞生產的品管
  • 開發用於癌症治療的現成CAR-T細胞療法，該療法源自於誘導多功能細胞

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章 幹細胞市場（依細胞類型）

  • 成體幹細胞
  • 人類胚胎幹細胞
  • 誘導性多功能細胞

第9章幹細胞市場：細胞來源

  • 同種異體
  • 自體移植

第 10 章 幹細胞市場：依技術

  • 生物列印
  • 細胞培養
    • 2D文化
    • 3D文化
  • 基因編輯
    • CRISPR
    • 轉錄活化因子樣效應核酸酶

第 11 章 幹細胞市場：依細胞來源

  • 脂肪組織
  • 羊膜細胞
  • 骨髓
  • 周邊血
  • 臍帶

第 12 章幹細胞市場：依應用

  • 細胞庫
    • 私人銀行
    • 公營銀行
  • 藥物研發與測試
    • 藥物篩檢
    • 毒性測試
  • 再生醫學
    • 心血管系統
    • 神經病學
    • 整形外科
  • 研究與開發

第13章 幹細胞市場（依最終用戶）

  • 生物製藥公司
  • 受託研究機構
  • 醫院和診所
  • 研究所

14.美洲幹細胞市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲幹細胞市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16.亞太幹細胞市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Danaher Corporation
    • Charles River Laboratories International, Inc.
    • Advanced Cell Technology, Inc.
    • AlloSource, Inc.
    • Anterogen Co., Ltd.
    • Athersys Inc.
    • Becton, Dickinson and Company
    • Bioheart Inc.
    • Biorestorative Therapies Inc.
    • BrainStorm Cell Therapeutics Inc.
    • Bristol-Myers Squibb Company
    • Cellartis AB
    • Cellular Engineering Technologies Inc.
    • Gamida Cell Ltd
    • GE HealthCare by General Electric Company
    • GenScript Biotech Corporation
    • Gilead Sciences, Inc.
    • HOLOSTEM Srl by Chiesi Farmaceutici SpA
    • JCR Pharmaceuticals Co., Ltd.
    • Lineage Cell Therapeutics, Inc.
    • Lonza Group
    • Merck KGaA
    • Novartis AG
    • Novo Holdings A/S
    • NuVasive Inc.
    • Pluristyx, Inc.
    • Sartorius AG
    • STEMCELL Group of Companies
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-434CCDA04CF2

The Stem Cells Market was valued at USD 14.22 billion in 2024 and is projected to grow to USD 15.72 billion in 2025, with a CAGR of 10.89%, reaching USD 26.45 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 14.22 billion
Estimated Year [2025] USD 15.72 billion
Forecast Year [2030] USD 26.45 billion
CAGR (%) 10.89%

Unveiling the Transformative Power and Emerging Potential of Stem Cell Innovations Across Therapeutic Research and Clinical Applications

Stem cell technologies have rapidly ascended from academic curiosities to the forefront of therapeutic innovation, fueling breakthroughs across regenerative medicine, drug discovery, and fundamental biology. Spanning the pioneering isolation of human embryonic stem cells to the contemporary mastery of induced pluripotent stem cells, this domain now underpins a wide array of clinical trials and commercial ventures. Insights into cellular differentiation, niche engineering, and immune modulation contextualize the multifaceted promise of these living therapeutics, offering potential treatments for cardiovascular disease, neurodegenerative disorders, and tissue injuries.

Amid growing demand for personalized medicine and precision therapies, stem cell platforms have attracted substantial investment, catalyzing collaborations between biopharma companies, research institutes, and technology providers. Simultaneously, advancements in culture systems, gene editing, and bioprinting have expanded both the scale and fidelity of cell-based processes, transitioning novel concepts from bench to bioreactor. Against a backdrop of increasingly complex regulations and evolving reimbursement models, organizations must navigate dynamic scientific, commercial, and policy landscapes to capture value.

This introduction frames a comprehensive exploration of core market drivers, disruptive shifts, tariff impacts, segmentation nuances, regional variances, company strategies, and actionable recommendations. By charting the intersecting trajectories of technology, policy, and enterprise initiatives, readers gain a cohesive understanding of how stem cell innovations are reshaping the future of healthcare and life sciences.

Charting Paradigm Shifts Driven by Regulatory Advances, Technological Breakthroughs, and Strategic Collaborations Reshaping the Stem Cell Landscape

The stem cell ecosystem is undergoing paradigm shifts fueled by regulatory advancements, technological breakthroughs, and strategic alliances. Emerging guidance from global health authorities now balances patient safety with expedited pathways for regenerative therapies, enabling accelerated approvals and compassionate use programs. In parallel, breakthroughs in genome engineering, such as enhanced CRISPR platforms and integrative sequencing, have unlocked unprecedented control over cellular identity and function.

Technological maturation of bioprinting, microfluidic culture systems, and organ-on-chip models is redefining tissue engineering, while novel biomaterials offer optimized scaffolding that mimics native extracellular matrices. These innovations, in turn, propel downstream applications such as drug screening, toxicity assessment, and personalized therapeutics. Meanwhile, large-scale manufacturing paradigms, including automated closed-loop bioreactors and real-time analytics, are shifting production from pilot stage to commercial viability.

Strategic collaborations between pharmaceutical developers, device manufacturers, academic laboratories, and contract research organizations are accelerating de-risking of complex projects. Consortium models, shared IP frameworks, and co-development agreements are breaking traditional silos, fostering co-innovation to tackle clinical translation challenges. As stakeholders adopt integrated development approaches, they are realigning investment portfolios and forging new value chains. These transformative shifts collectively reshape the competitive landscape, establishing a foundation for the next wave of stem cell-driven healthcare solutions and reshaping expectations around efficacy, safety, and scalability.

Analyzing the Extensive Cumulative Impact of United States Tariffs Implemented in 2025 on Stem Cell Supply Chains and Research Dynamics

The introduction of United States tariffs in 2025 has introduced notable complexities across global stem cell supply chains and research operations. While aimed at protecting domestic manufacturing sectors, these measures have reverberated through the procurement of essential reagents, specialized equipment, and raw materials critical to cell culture, gene editing, and bioprinting processes. Consequently, laboratories and production facilities have confronted increased costs for imported items, prompting procurement teams to explore alternative suppliers or local manufacturing partners to mitigate budgetary pressures.

Operational delays have emerged as shipment schedules adjust to new customs protocols, extending lead times for key consumables such as growth factors, culture media, and high-precision instrumentation. These disruptions carry significant implications for time-sensitive experiments and ongoing clinical trial activities, where consistency and reproducibility are paramount. Organizations that had built just-in-time inventory strategies now reassess safety stock levels and distribution networks to maintain continuity under evolving tariff regimes.

In response, strategic buyers are intensifying collaboration with domestic distributors to secure favorable terms, while some academic and commercial entities are repatriating portions of their supply chains to reclaim cost certainty. In parallel, industry stakeholders are lobbying for tariff exemptions on biotechnology essentials, advocating the critical nature of these materials in advancing human health. The cumulative impact of these policies underscores the importance of supply chain resilience and adaptive sourcing strategies as foundational elements of sustainable stem cell research and manufacturing.

Unlocking Key Segmentation Insights Spanning Cell Types Sources Technologies Applications and End Users to Illuminate Market Opportunities

Diving into segmentation insights reveals a nuanced landscape shaped by diverse cell type classifications, source origins, technology platforms, tissue inputs, applications, and end user categories. Examining cell types illustrates the distinct trajectories of adult stem cells alongside human embryonic stem cells and induced pluripotent stem cells, each offering unique advantages in differentiation potential, ethical considerations, and scalability. Further segmentation according to cell source contrasts allogeneic therapies with autologous approaches, delineating trade-offs between off-the-shelf availability and personalized compatibility.

Technological segmentation uncovers the rapid ascendance of bioprinting alongside advanced cell culture methodologies, with two-dimensional systems evolving into physiologically relevant three-dimensional environments. Concurrently, gene editing technologies, anchored by CRISPR advancements and transcription activator-like effector nucleases, enable precision modifications that enhance therapeutic efficacy and safety. Tissue source segmentation highlights critical material inputs such as adipose tissue, amniotic cells, bone marrow, peripheral blood, and umbilical cord, each presenting specific extraction, expansion, and regulatory considerations.

From an application standpoint, cell banking divides into private and public repositories, while drug discovery and testing programs leverage pharmaceutical screening and toxicity assays to de-risk novel compounds. Regenerative medicine projects target cardiovascular, neurological, and orthopedic indications, reflecting both unmet clinical needs and reimbursement landscapes. Finally, end users spanning biopharmaceutical companies, contract research organizations, hospitals and clinics, and research institutes drive demand patterns and service offerings. This multifaceted segmentation framework provides stakeholders with granular touchpoints to tailor strategies, optimize resource allocation, and uncover white-space opportunities across the evolving stem cell market.

Examining Regional Dynamics Highlighting Emerging Growth Drivers and Distinct Challenges Across the Americas Europe Middle East Africa and Asia Pacific

Regional dynamics in the stem cell arena reveal varied growth trajectories, innovation clusters, and regulatory frameworks that shape global adoption patterns. Within the Americas, mature markets exhibit robust infrastructure for clinical trials and manufacturing, anchored by well-funded research institutes and established biopharma players. Regulatory agencies in this region continue to refine expedited pathways, striking a balance between patient safety and accelerated access to pioneering therapies. Cross-border collaborations and shared innovation hubs further bolster ecosystem connectivity.

In Europe, Middle East and Africa, a mosaic of regulatory approaches underscores the complexity of harmonizing standards across multiple jurisdictions. While certain European nations spearhead adaptive licensing schemes and advanced therapy classifications, emerging markets in the Middle East and Africa are cultivating nascent research centers and investment incentives. Stakeholders in this region navigate intricate compliance landscapes while capitalizing on expanding public and private funding opportunities.

Asia-Pacific stands out as a vibrant frontier, driven by rapid technological adoption, supportive government policies, and growing interest in regenerative solutions. Countries across this region are streamlining approval processes and investing heavily in domestic biomanufacturing capabilities. Strategic partnerships between multinational corporations and local players accelerate technology transfer and capacity building, positioning Asia-Pacific for a significant share of future advances. Recognizing these regional nuances enables organizations to align market entry strategies, prioritize regulatory pathways, and adapt commercial models for sustainable growth across diverse geographies.

Dissecting Leading Company Strategies Innovations and Collaborations Shaping Competitive Dynamics within the Global Stem Cell Research Market

Leading organizations within the stem cell domain are deploying differentiated strategies to gain competitive advantage, combining deep scientific expertise with robust partnership networks and agile business models. Some of the foremost biopharmaceutical companies are integrating end-to-end platforms that link upstream cell sourcing, gene editing capabilities, and downstream manufacturing, thereby ensuring consistency and traceability across the value chain. These integrated players often pursue in-licensing arrangements and co-development deals with specialized technology firms to accelerate pipeline diversification and reduce time-to-clinic.

Contract research organizations and cell therapy contract manufacturers have expanded service portfolios to include process development, scale-up expertise, and regulatory consulting, recognizing that turnkey solutions foster stronger client relationships and higher entry barriers for competitors. Simultaneously, academic spin-outs and small biotech ventures are forging strategic alliances with larger incumbents to secure capital, access specialized facilities, and navigate complex approval pathways. These collaborations frequently involve milestone-based licensing agreements and shared risk-reward frameworks.

Moreover, technology innovators in bioprinting and advanced culture systems are partnering with biopharma giants to co-create next-generation test platforms that reduce reliance on animal models while offering human-relevant data. Company strategies increasingly emphasize flexible manufacturing modules, digital twins, and real-time analytics, enabling rapid process optimization and lower operational costs. By examining these company initiatives, stakeholders can benchmark best practices, identify potential partners, and anticipate shifts in competitive positioning driven by novel alliances and platform expansions.

Formulating Actionable Recommendations for Industry Leaders to Foster Sustainable Growth Drive Innovation and Navigate Evolving Regulatory and Market Trends

To maintain momentum in the evolving stem cell ecosystem, industry leaders should adopt a proactive, multidisciplinary approach that aligns scientific innovation with operational excellence and regulatory acumen. Firstly, organizations must invest in integrated digital frameworks that unify data from R&D, manufacturing, and clinical operations, empowering real-time decision-making and predictive analytics to streamline workflows. Concurrently, establishing cross-functional governance teams ensures that regulatory requirements, quality standards, and ethical considerations are embedded from project inception through commercialization.

Secondly, strategic sourcing initiatives should prioritize supply chain resilience by cultivating diverse vendor relationships, localizing critical material production, and implementing advanced inventory management systems. This mitigates exposure to external policy shifts, such as tariffs, and enhances continuity of research and manufacturing activities. Thirdly, fostering collaborative innovation through consortium models and public-private partnerships accelerates technology validation and de-risking, while shared IP frameworks promote broader adoption of best-in-class methodologies.

Additionally, companies should align portfolio decisions with patient and payer perspectives, integrating health economics and outcomes research early in development to support value propositions. Tailored engagement with regulators, including adaptive trial designs and rolling submissions, can expedite approvals while maintaining rigorous safety standards. Finally, cultivating talent pipelines that blend expertise in cell biology, bioengineering, data science, and regulatory strategy will underpin sustained leadership. By implementing these actionable recommendations, stakeholders can navigate complexity, unlock new market segments, and drive tangible impact across the stem cell landscape.

Detailing Comprehensive Research Methodology Integrating Data Sources Stakeholder Engagement and Analytical Frameworks for Robust Stem Cell Market Intelligence

The research methodology underpinning this report integrates a blend of qualitative and quantitative approaches designed to capture the multifaceted nature of the stem cell sector. Initial secondary research involved exhaustive reviews of peer-reviewed journals, regulatory filings, patent landscapes, conference proceedings, and technology white papers to map scientific advancements and policy developments. These insights were triangulated with proprietary databases and trade publications to validate emerging trends and identify leading players.

Complementing secondary sources, primary research encompassed in-depth interviews with senior executives, R&D leaders, manufacturing specialists, regulatory authorities, and end users across biopharmaceutical companies, contract research organizations, hospitals, and research institutes. These dialogues provided context on strategic priorities, investment horizons, technology adoption drivers, and operational challenges. Survey instruments were deployed to capture quantitative measures related to segmentation parameters, regional priorities, and tariff impact perceptions.

Analytical frameworks such as Porter's Five Forces and SWOT analyses were applied to evaluate competitive pressures and organizational strengths. Segmentation modeling was conducted by synthesizing cell type, cell source, technology, tissue source, application, and end user dimensions, enabling granular scenario planning. Regional assessments incorporated macroeconomic indicators, regulatory indices, and healthcare infrastructure metrics. Iterative validation sessions with domain experts ensured the robustness of findings and the practical relevance of recommendations. This comprehensive research methodology delivers a holistic, evidence-based view of the global stem cell market ecosystem.

Summarizing Key Findings Strategic Implications and Future Outlook for Stakeholders Engaged in the Stem Cell Ecosystem and Translational Research Endeavors

This executive summary has distilled key insights into the dynamic field of stem cell research and its expanding role in healthcare innovation. We have examined how emerging regulatory pathways, technological breakthroughs, and strategic collaborations are collectively reshaping the landscape, while assessing the reverberations of newly imposed tariffs on supply chains and research continuity. A detailed segmentation analysis has illuminated discrete market dimensions across cell types, sources, technologies, tissue inputs, applications, and end users, offering stakeholders targeted entry points and white-space opportunities.

Regional insights spotlight the maturing infrastructures of the Americas, the regulatory diversity of Europe, Middle East and Africa, and the rapid ascendance of the Asia-Pacific region as a hub for both innovation and scale. Company profiles reveal an ecosystem where integrated platforms, consortium models, and agile manufacturing strategies define competitive positioning. Actionable recommendations emphasize integrated data frameworks, supply chain resilience, collaborative innovation, patient-centric portfolio alignment, and adaptive regulatory engagement as cornerstones for sustained leadership.

Collectively, these findings underscore a moment of inflection for the stem cell sector, where scientific promise converges with commercial pragmatism and policy momentum. By leveraging the insights, methodologies, and strategic imperatives outlined here, stakeholders can refine their roadmaps, mitigate risks, and accelerate the translation of cell-based therapies from concept to clinic. The future of regenerative medicine hinges on these convergent efforts, heralding a new era of human-centred therapeutic solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Advances in induced pluripotent stem cells for personalized disease modeling and high throughput drug screening
  • 5.2. Bioprinting of functional tissues using scaffold free stem cell spheroids for complex organ regeneration
  • 5.3. Rapid development of allogeneic mesenchymal stem cell therapies targeting inflammatory bowel disease symptoms
  • 5.4. Emergence of CRISPR edited hematopoietic stem cell therapies for treatment of sickle cell disease complications
  • 5.5. First regulatory clearances for allogeneic neural stem cell implants in spinal cord injury repair protocols
  • 5.6. Commercialization of extracellular vesicle based diagnostics derived from stem cell secretome for early disease detection
  • 5.7. Strategic partnerships between biotech innovators and pharmaceutical companies to accelerate stem cell heart failure treatments
  • 5.8. Investment trends in automated stem cell manufacturing platforms to scale production and reduce therapy costs
  • 5.9. Integration of artificial intelligence driven predictive differentiation models for quality control in stem cell production
  • 5.10. Development of off the shelf CAR T cell therapies derived from induced pluripotent stem cells for cancer treatment

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Stem Cells Market, by Cell Type

  • 8.1. Introduction
  • 8.2. Adult Stem Cells
  • 8.3. Human Embryonic Stem Cells
  • 8.4. Induced Pluripotent Stem Cells

9. Stem Cells Market, by Cell Source

  • 9.1. Introduction
  • 9.2. Allogeneic
  • 9.3. Autologous

10. Stem Cells Market, by Technology

  • 10.1. Introduction
  • 10.2. Bioprinting
  • 10.3. Cell Culture
    • 10.3.1. 2D Culture
    • 10.3.2. 3D Culture
  • 10.4. Gene Editing
    • 10.4.1. CRISPR
    • 10.4.2. Transcription Activator-Like Effector Nuclease

11. Stem Cells Market, by Cell Source

  • 11.1. Introduction
  • 11.2. Adipose Tissue
  • 11.3. Amniotic Cells
  • 11.4. Bone Marrow
  • 11.5. Peripheral Blood
  • 11.6. Umbilical Cord

12. Stem Cells Market, by Application

  • 12.1. Introduction
  • 12.2. Cell Banking
    • 12.2.1. Private Banking
    • 12.2.2. Public Banking
  • 12.3. Drug Discovery & Testing
    • 12.3.1. Pharmaceutical Screening
    • 12.3.2. Toxicity Testing
  • 12.4. Regenerative Medicine
    • 12.4.1. Cardiovascular
    • 12.4.2. Neurology
    • 12.4.3. Orthopaedics
  • 12.5. Research & Development

13. Stem Cells Market, by End User

  • 13.1. Introduction
  • 13.2. Biopharmaceutical Companies
  • 13.3. Contract Research Organizations
  • 13.4. Hospitals & Clinics
  • 13.5. Research Institutes

14. Americas Stem Cells Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Stem Cells Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Stem Cells Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Danaher Corporation
    • 17.3.2. Charles River Laboratories International, Inc.
    • 17.3.3. Advanced Cell Technology, Inc.
    • 17.3.4. AlloSource, Inc.
    • 17.3.5. Anterogen Co., Ltd.
    • 17.3.6. Athersys Inc.
    • 17.3.7. Becton, Dickinson and Company
    • 17.3.8. Bioheart Inc.
    • 17.3.9. Biorestorative Therapies Inc.
    • 17.3.10. BrainStorm Cell Therapeutics Inc.
    • 17.3.11. Bristol-Myers Squibb Company
    • 17.3.12. Cellartis AB
    • 17.3.13. Cellular Engineering Technologies Inc.
    • 17.3.14. Gamida Cell Ltd
    • 17.3.15. GE HealthCare by General Electric Company
    • 17.3.16. GenScript Biotech Corporation
    • 17.3.17. Gilead Sciences, Inc.
    • 17.3.18. HOLOSTEM S.r.l. by Chiesi Farmaceutici S.p.A
    • 17.3.19. JCR Pharmaceuticals Co., Ltd.
    • 17.3.20. Lineage Cell Therapeutics, Inc.
    • 17.3.21. Lonza Group
    • 17.3.22. Merck KGaA
    • 17.3.23. Novartis AG
    • 17.3.24. Novo Holdings A/S
    • 17.3.25. NuVasive Inc.
    • 17.3.26. Pluristyx, Inc.
    • 17.3.27. Sartorius AG
    • 17.3.28. STEMCELL Group of Companies
    • 17.3.29. Takeda Pharmaceutical Company Limited
    • 17.3.30. Thermo Fisher Scientific Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. STEM CELLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. STEM CELLS MARKET: RESEARCHAI
  • FIGURE 28. STEM CELLS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. STEM CELLS MARKET: RESEARCHCONTACTS
  • FIGURE 30. STEM CELLS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STEM CELLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STEM CELLS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL STEM CELLS MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELLS MARKET SIZE, BY ADULT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STEM CELLS MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL STEM CELLS MARKET SIZE, BY BIOPRINTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STEM CELLS MARKET SIZE, BY BIOPRINTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL STEM CELLS MARKET SIZE, BY 2D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STEM CELLS MARKET SIZE, BY 2D CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL STEM CELLS MARKET SIZE, BY 3D CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STEM CELLS MARKET SIZE, BY 3D CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL STEM CELLS MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STEM CELLS MARKET SIZE, BY CRISPR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL STEM CELLS MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STEM CELLS MARKET SIZE, BY TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STEM CELLS MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL STEM CELLS MARKET SIZE, BY AMNIOTIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STEM CELLS MARKET SIZE, BY AMNIOTIC CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STEM CELLS MARKET SIZE, BY BONE MARROW, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STEM CELLS MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STEM CELLS MARKET SIZE, BY UMBILICAL CORD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL STEM CELLS MARKET SIZE, BY PRIVATE BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STEM CELLS MARKET SIZE, BY PRIVATE BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL STEM CELLS MARKET SIZE, BY PUBLIC BANKING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STEM CELLS MARKET SIZE, BY PUBLIC BANKING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL STEM CELLS MARKET SIZE, BY PHARMACEUTICAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STEM CELLS MARKET SIZE, BY PHARMACEUTICAL SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL STEM CELLS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STEM CELLS MARKET SIZE, BY TOXICITY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STEM CELLS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL STEM CELLS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STEM CELLS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELLS MARKET SIZE, BY ORTHOPAEDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STEM CELLS MARKET SIZE, BY ORTHOPAEDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL STEM CELLS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STEM CELLS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL STEM CELLS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STEM CELLS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STEM CELLS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STEM CELLS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. AMERICAS STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. AMERICAS STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 98. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 119. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES STEM CELLS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 163. CANADA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. CANADA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 183. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 184. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 185. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 203. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 204. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 205. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 206. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 207. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 223. ARGENTINA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 224. ARGENTINA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 225. ARGENTINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 226. ARGENTINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 227. ARGENTINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 228. ARGENTINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 229. ARGENTINA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ARGENTINA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA STEM CELLS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 265. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 267. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 269. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 270. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 271. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 272. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 274. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 281. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. GERMANY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 285. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 287. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 289. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. GERMANY STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 293. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 295. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 297. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 299. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 301. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 303. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 305. FRANCE STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 307. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 309. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 311. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 312. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 313. FRANCE STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 314. FRANCE STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 315. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 316. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 317. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 318. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 319. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 321. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 324. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 325. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 327. RUSSIA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 328. RUSSIA STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 329. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 330. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 331. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 332. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 333. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 335. RUSSIA STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 336. RUSSIA STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 337. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 338. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 339. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 340. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 341. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 343. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 346. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 347. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 349. ITALY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 350. ITALY STEM CELLS MARKET SIZE, BY CELL CULTURE, 2025-2030 (USD MILLION)
  • TABLE 351. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2024 (USD MILLION)
  • TABLE 352. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2025-2030 (USD MILLION)
  • TABLE 353. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 354. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 355. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 356. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 357. ITALY STEM CELLS MARKET SIZE, BY CELL BANKING, 2018-2024 (USD MILLION)
  • TABLE 358. ITALY STEM CELLS MARKET SIZE, BY CELL BANKING, 2025-2030 (USD MILLION)
  • TABLE 359. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2024 (USD MILLION)
  • TABLE 360. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2025-2030 (USD MILLION)
  • TABLE 361. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 362. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2030 (USD MILLION)
  • TABLE 363. ITALY STEM CELLS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 364. ITALY STEM CELLS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 365. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 366. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
  • TABLE 367. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 368. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025-2030 (USD MILLION)
  • TABLE 369. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 370. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 371. SPAIN STEM CELLS MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILL